Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To study the safety and effectiveness of RV-1770 Respiratory Syncytial Virus (RSV) mRNA vaccine

Next Previous
Trial Profile

To study the safety and effectiveness of RV-1770 Respiratory Syncytial Virus (RSV) mRNA vaccine

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RV-1770 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions

Most Recent Events

  • 21 Dec 2023 New trial record
  • 18 Dec 2023 According to a RNAimmune media release, the company has obtained a green light from the U.S. Food and Drug Administration (FDA) to proceed with its Investigational New Drug application for Phase I clinical trials of RV-1770, an mRNA vaccine targeting the human Respiratory Syncytial Virus (RSV).
  • 18 Dec 2023 According to a RNAimmune media release, the U.S. Food and Drug Administration (FDA) granted IND clearance for its RV-1770 Respiratory Syncytial Virus (RSV) mRNA vaccine.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top